Cosmos Health Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023; unaudited. Cosmos Health operates in pharmaceutical and healthcare distribution and sells proprietary nutraceuticals, including Sky Premium Life and Mediterranation. It filed the report on August 14, 2023.
Financial performance
- Q2 revenue: $12.36 million, down 6.4% from $13.21 million. Six-month revenue: $24.71 million, down 6.0% from $26.28 million. Greece remained the dominant reported market.
- Gross profit and margin: Q2 gross profit was $0.95 million, down 48.7%, with a 7.7% gross margin versus 14.0%. Six-month gross profit was $1.90 million, down 49.1%, with a 7.7% margin versus 14.2%.
- Operating result: Q2 operating loss was $2.58 million versus $0.07 million; six-month operating loss was $5.23 million versus operating income of $0.17 million.
- Net loss: Q2 net loss was $0.98 million versus $1.24 million. Six-month net loss was $1.44 million versus $1.04 million. The 2022 common-stockholder loss was much larger because of substantial deemed dividends on preferred stock and warrants; those items did not recur in 2023.
- Other income and unusual items: Six-month results included a $1.63 million bargain-purchase gain on Cana and $1.91 million of gains on debt extinguishment. These materially offset operating losses. Q2 included the $1.63 million Cana bargain-purchase gain.
- Cash flow: Six-month operating cash use was $12.06 million versus $3.02 million a year earlier; investing cash use was $8.45 million versus $0.16 million, including Cana acquisition spending. Financing provided $2.06 million. Cash fell $18.52 million to $2.23 million.
- Liquidity: Working capital was $23.98 million, down from $34.30 million at year-end 2022. Current assets were $44.21 million and current liabilities $20.23 million. Net accounts receivable was $23.57 million, with a $8.15 million allowance for doubtful accounts.
- Debt and obligations: Lines of credit were $4.73 million; notes payable were $3.41 million, including $0.89 million current and $2.52 million long-term. Total liabilities were $24.55 million. The company reported compliance with its line-of-credit covenants.
- Equity: Stockholders’ equity was $43.67 million. The company reported 10.94 million common shares outstanding at June 30 and 4.19 million warrants outstanding.
Changes and business developments
- Management attributed lower gross profit primarily to reduced and discounted sales of SkyPharm nutraceuticals as it sought to reduce overdue receivables from exclusive distributor Medihelm. Higher raw-material costs also weighed on costs of goods sold.
- Operating expenses rose substantially, particularly general and administrative expense, compensation and bonuses, and sales and marketing. Management cited higher management compensation and bonuses, including stock-based compensation.
- On June 30, Cosmos acquired Greek pharmaceutical manufacturer Cana for stated consideration of $5.47 million, including a previously advanced secured loan and common shares. The preliminary purchase-price allocation produced a $1.63 million bargain-purchase gain. Cana added manufacturing facilities and assets.
- The company also acquired the ZipDoctor telehealth platform and a Greek distribution network/customer base from Bikas, and purchased a building. Property and equipment rose to $10.69 million from $1.82 million at year-end.
- In January, Cosmos terminated its Marathon distribution and equity agreement; the resulting write-off of a share-settled debt obligation contributed to the debt-extinguishment gain.
Outlook, risks and controls
- No quantified revenue, profit or cash-flow guidance was provided. Management described its outlook as positive and plans to expand distribution, product offerings, markets and acquisitions. It targeted up to 150 own-brand nutraceutical SKUs by year-end 2023.
- Management expects to use available cash and may rely on debt or equity financing, investing activities or management loans; it stated management is not obligated to provide funding. It warned that failure to meet requirements could jeopardize Nasdaq quotation and SEC reporting status.
- Key stated risks include competition, pricing and reimbursement pressure, healthcare spending, supply-chain disruption, regulation, foreign exchange, availability of capital and the continuing Ukraine conflict’s potential indirect effects.
- Revenue recognition incorporates an estimate for variable consideration related to Medihelm’s overdue receivables; $170,375 was deferred from six-month sales. Related-party balances and transactions are significant, including supplier prepayments and loans.
- Management concluded disclosure controls were partially effective, citing previously identified material weaknesses involving segregation of duties and internal-control structure review. Remediation work is ongoing.
- Pending legal matters include a tax-audit appeal seeking recovery of approximately €91,652 already paid; the filing states the listed matters are not expected to have a material financial or operational impact. No off-balance-sheet arrangements were reported.
- After quarter-end, a July registered direct offering and concurrent warrant placement generated approximately $5.25 million gross and $4.8 million net proceeds.
Important facts for investors to verify
- Collection progress and credit exposure to Medihelm, including the adequacy of the receivables allowance and the effect of discounted nutraceutical sales on margins.
- Cash requirements and funding plans given $2.23 million of June 30 cash, $12.06 million of six-month operating cash use, and management’s stated reliance on potential external financing.
- Cana’s post-acquisition operating contribution, the assumptions behind its preliminary valuation and bargain-purchase gain, and any integration costs or future funding needs.
- Reconciliation of share counts: the filing reports 10.94 million shares outstanding at June 30, but 10,620,670 as of August 14; it also describes a July offering involving 2,116,936 shares. Confirm the fully diluted and post-offering share count.
- Progress and evidence of remediation of the disclosed control weaknesses, and the status of related-party balances, including supplier advances and receivables.
- Renewal and availability of credit facilities, repayment terms for outstanding debt, and ongoing compliance with covenants.